AMG 333

Drug Profile

AMG 333

Alternative Names: AMG-333

Latest Information Update: 13 Feb 2015

Price : $50

At a glance

  • Originator Amgen
  • Class Antimigraines
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Migraine

Most Recent Events

  • 01 Nov 2014 Amgen completes a phase I trial in Migraine (prevention) in USA (NCT01953341)
  • 05 May 2014 Amgen plans a phase I trial for Migraine (prevention) in USA (NCT02132429)
  • 01 May 2014 Amgen initiates a phase I trial for Migraine (prevention) in USA (NCT02132429)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top